The Impact of the GOLD 2023 on Clinical Treatment in Northeast China

Jiawei Zhou1 Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, People’s Republic of ChinaView further author information

Xiaomeng Li1 Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, People’s Republic of ChinaView further author information

Xiang Li2 Department of Respiratory and Critical Care Medicine, Central Hospital Affiliated to Shenyang Medical College, Shenyang, People’s Republic of ChinaView further author information

Na Wang3 Department of Respiratory and Critical Care Medicine, Tieling County Central Hospital, Tieling, People’s Republic of ChinaView further author information

Xu Cai4 Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of ChinaView further author information

Lei Zhang1 Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, People’s Republic of ChinaView further author information

Chen Li1 Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, People’s Republic of ChinaView further author information

Wei Wang1 Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information

Na Yu1 Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, People’s Republic of ChinaView further author information

show all

References

GOLD. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2023 report [OL]; 2023. Available from: https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf. Accessed November 23, 2022.
Google Scholar
GOLD. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2017 report [OL]. Available from: https://goldcopd.org/. Accessed November 23, 2022.
Google Scholar
Li Y, Lim J, Stemkowski S, Kaila S, Renda A, Shaikh A. Initiation of triple therapy maintenance treatment among patients with COPD. Am J Manag Care. 2020;26(4):e106–e112.
PubMed Web of Science ®Google Scholar
Meeraus W, Wood R, Jakubanis R, et al. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners. Int J Chron Obstruct Pulmon Dis. 2019;14:51–63. doi:10.2147/COPD.S181224
PubMed Web of Science ®Google Scholar
Yang T, Cai B, Cao B, et al. Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study. Respir Res. 2022;23(1):106. doi:10.1186/s12931-022-02021-w
PubMed Web of Science ®Google Scholar
Bloom CI, Montonen J, Jöns O, Garry EM, Bhatt SP. First maintenance therapy for chronic obstructive pulmonary disease: retrospective analyses of US and UK healthcare databases. Pulm Ther. 2022;8(1):57–74. doi:10.1007/s41030-021-00179-0
PubMedGoogle Scholar
Milea D, Yeo SH, Nam Y, et al. Long-acting bronchodilator use in chronic obstructive pulmonary disease in primary care in New Zealand: a retrospective study of treatment patterns and evolution using the HealthStat Database. Int J Chron Obstruct Pulmon Dis. 2021;16:1075–1091. doi:10.2147/COPD.S290887
PubMed Web of Science ®Google Scholar

The Impact of the GOLD 2023 on Clinical Treatment in Northeast China

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The Impact of the GOLD 2023 on Clinical Treatment in Northeast China

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date